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Low-density lipoprotein receptormicrobial protein which affects Japanese encephalitis virus (JEV) activity. Binding
of lactoferrin to cell surface expressed heparan sulfate (HS), one possible receptor for JEV, has been
postulated to be the possible mechanism of anti-JEV antiviral activity. In this study, we evaluate the effects of
bovine lactoferrin (bLF) against JEV infection in vitro, using both wild-type (WT) and laboratory-adapted
strains. bLF inhibited the infectivity of all the JEV strains tested. In particular the infectivity of the HS-adapted
JEV strains was strongly reduced, whereas the non HS-adapted JEV strains were inhibited to lesser extent.
Using both HS-adapted CJN-S1 and non HS-adapted CJN-L1 viruses, the results showed that bLF inhibited the
early events essential to initiate JEV infection, which includes blocking virus attachment to cellular
membranes and reducing viral penetration. This anti-JEV activity was the highest using HS-adapted CJN-S1
strain on HS-expressed CHO-K1 cells. Also, binding of bLF to heparin-sepharose blocked JEV binding; and
soluble HS attenuated the anti-JEV activity of bLF. The results support the premise that the interaction of bLF
with cell surface expressed glycosaminoglycans, in particular the highly sulfated HS, plays an essential role in
the antiviral activity of bLF. However, bLF was functional in inhibiting CJN-S1 entry into HS-deﬁcient CHO-
pgsA745 cells, and bLF-treated CHO-K1 and -pgsA745 cells also prevented non HS-adapted CJN-L1 virus
entry, indicating that a non-HS pathway may be involved in bLF inhibition of JEV entry. The low-density
lipoprotein receptor (LDLR), possibly involved in the entry of several RNA viruses, also binds to bLF. We found
that both rLDLR and anti-LDLR antibodies reduced the effectiveness of bLF inhibition of JEV infection. This
ﬁnding provided evidence to suggest that cell surface-expressed LDLR may play a role in JEV infection,
especially for non HS-adapted strains.
© 2008 Elsevier Inc. All rights reserved.IntroductionJapanese encephalitis virus (JEV) is an important mosquito-borne
pathogen, which is the leading cause of encephalitis in humans in
Asian countries. JEV infections cause a broad spectrum of clinical
symptoms, ranging from asymptomatic, fever, and encephalitis to
death. Infections leading to overt encephalitis are estimated to be 1 in
20 to 1000 cases (Brandt, 1990; Grossman et al., 1973; Huang, 1982),
but approximately 25% of encephalitic patients die and 50% of the
survivors develop permanent neurologic and/or psychiatric sequelae.
Beginning in 1968, a nation-wide vaccination program for children
against JEV was implemented in Taiwan, using mouse-brain-derived
and formalin-inactivated JEV Nakayama vaccine. Since then the
conﬁrmed cases of JEV infection has dramatically dropped to about
20–30 cases annually (Wu et al., 1999).Institute of Veterinary Public
uang Road, Taichung, 40027
hiou).
l rights reserved.The ﬁrst step in viral infection is the attachment to the host cell
followed by penetration of the cell membrane. This initial step in JEV
infection involves the interaction of glycosaminoglycans (GAGs), in
particular the highly sulfated form of GAGs (heparan sulfate, HS), on the
cell surface and the viral envelope (E) glycoproteins (Chiou et al., 2005;
Liu et al., 2004; Su et al., 2001). Mutations in the amino acid residues 49,
138, 306, or 389 of JEV E protein have been implicated in changing the
interaction with HS, resulting in altering plaque size, viral entry,
neurovirulence, and neuroinvasiveness (Chiou et al., 2005; Lee et al.,
2004; Lee and Lobigs, 2002; Liu et al., 2004; Su et al., 2001). In additional
to GAGs, several plasma membrane-associated, heparinase-resistant
proteins could possibly be part of a receptor complex for JEV on
mammalian or mosquito cells (Chen et al., 1996; Chu et al., 2005).
Lactoferrin (LF) is an 80 kDamulti-functional glycoproteinwhich is
present in plasma and external secretions, like milk and tears (Masson
et al., 1969; Weinberg, 2001). It is primarily an iron-binding protein
that functions in iron transport in intestines (Kuwata et al., 1998), and
also is associated with non-speciﬁc immune responses involved in
suppressing a variety of infections including bacteria, fungus, and
viruses (Buckley et al., 2003; Rocco et al., 1998; Ueta et al., 2001; Yoo et
144 Y.-J. Chien et al. / Virology 379 (2008) 143–151al., 1998). LF inhibits virus entry by binding directly to the virus
particle or to membrane-bound HS (Andersen et al., 2003, 2001;
Harmsen et al., 1995; Marchetti et al., 1996). Both human and bovine
LF (bLF) have a relatively high net positive charge and may interact
with negatively charged GAGs expressed on target cells (El Yazidi-
Belkoura et al., 2001), which could result in antiviral activity. In
addition to HS, LF also binds to the low-density lipoprotein receptor
(LDLR) and LDLR-related protein (LRP) (Huettinger et al., 1998).
Previously, we have demonstrated that highly sulfated GAGs, such
as HS, are important receptors for JEV in vitro, and have identiﬁed two
HS-binding motifs in the E glycoprotein of JEV (Chiou et al., 2005; Liu
et al., 2004). The focus of this study was to investigate the antiviral
activity exerted by the HS-binding protein, bLF, and to study a possible
correlation between GAG afﬁnity and antiviral activity. Our results
show that bLF inhibited both wild-type and laboratory-adapted JEV
strains, and that the antiviral activity of bLF correlated with the HS-
binding afﬁnity of JEV in vitro. In addition, the anti-JEV activity of bLF
may also involve binding to LDLR.Results
Inhibition of JEV infection by bLF
To determine whether bLF has antiviral activity against JEV, we
performed a plaque reduction assay in the presence of bLF. BHK-21
cells were pre-incubated with 200 μg/ml of bLF, and the same
concentration of bLF was maintained in the overlay medium through-
out the infection. No cytotoxic effect of bLF was observed during the
experiments. The bLF-treated cells were infected with 200 plaque
forming unit (PFU) of eleven JEV strains, including three ﬁeld-isolated
wild-type (WT) strains and eight laboratory-adapted strains derived
from them (Table 1). Infection of BHK-21 cells by all of the JEV strains
were drastically inhibited by the presence of bLF, range from 17.3% to
95.8% (Table 1). Based on our previous studies, these strains could be
classiﬁed into HS-adapted or non HS-adapted virus according to the
binding afﬁnity to heparan sulfate (Chiou and Chen, 2007; Chiou et al.,
2005; Liu et al., 2004). The infectivity of the HS-adapted JEV strains,
excluding CC27-S6,measured by plaque number, was strongly reduced
in the presence of bLF. By contrast, the non HS-adapted JEV strains
were only slightly inhibited by bLF, except CC27 and it derivates CC27-
L1 and CC27-L3. HS-adapted CJN-S1 and non HS-adapted CJN-L1
strains showed the highest and lowest inhibition, respectively, by bLF
and were thus selected for the following experiments to study the
mechanism by which bLF inhibited JEV infection.
The plaque reduction assays conﬁrmed that bLF-treated BHK-21
cells inhibited JEV infection in a dose-dependentmanner (Fig. 1A). The
estimated 50% inhibitory concentration (IC50)was 26.1 and 518.3 μg/mlTable 1
Antiviral effect of bovine lactoferrin (bLF) against various strains of wide-type and
laboratory-adapted Japanese encephalitis virus (JEV)a
Virus Sourceb HS afﬁnityb % inhibition by bLFc
T1P1 Mosquito isolate Low (non HS-adapted) 17.6±5.9
T1P1-L4 Plaque—puriﬁed from T1P1 Low (non HS-adapted) 18.1±11.5
T1P1-S1 Plaque—puriﬁed from T1P1 High (HS-adapted) 95.6±2.7
CJN human brain isolate High (HS-adapted) 90.3±3.4
CJN-L1 Plaque—puriﬁed from CJN Low (non HS-adapted) 17.3±1.7
CJN-S1 Plaque—puriﬁed from CJN High (HS-adapted) 95.8±1.6
CC27 mosquito isolate Low (non HS-adapted) 70.3±9.3
CC27-L1 Plaque—puriﬁed from CC27 Low (non HS-adapted) 87.2±3.7
CC27-L3 Plaque—puriﬁed from CC27 Low (non HS-adapted) 56.5±10.3
CC27-S6 Plaque—puriﬁed from CC27 High (HS-adapted) 35.4±7.7
CC27-S8 Plaque—puriﬁed from CC27 Low (non HS-adapted) 31.8±14.2
a The assessment of anti-JEV activity of bLF was performed on BHK-21 cells.
b See reference (Chiou and Chen, 2007; Chiou et al., 2005; Liu et al., 2004).
c Before and after infection with 200 PFU JEV, BHK-21 cells were cultured with
medium containing 200 μg/ml bLF.
Fig. 1. Inhibitory effect of bLF against JEV infection. The BHK-21 cells were infected with
200 PFU JEV CJN-L1 or CJN-S1 strains using various conditions. The bLF was presented
both before and throughout the infection (A), the virus was pre-mixed with bLF at 4 °C
for 1 h (B), and the cells were pre-treated with bLF at 4 °C for 1 h (C).for CJN-S1 and CJN-L1, respectively. In order to determinewhether the
inhibitory effect was due to the direct interaction of bLF with the virus
or with the cells, we pre-incubated JEV CJN-S1 and CJN-L1 with 100 or
200 μg/ml bLF in a small volume. The bLF-virus mixture was then
diluted to a ﬁnal concentration of 0.09 μg/ml bLF before infecting BHK-
21 cells. No cytopathic effect was observed in the control cells treated
with the same ﬁnal concentration of bLF, and no inhibitory effectswere
observed against CJN-S1 and CJNL1 infection when the viruses were
pre-incubated with a high concentration of bLF and diluted before
infection (Fig. 1B). In the next experiments, the BHK-21 cells were pre-
treated with various concentrations of bLF (0.1 to 200 μg/ml) which
was removedbefore incubationwith JEV. The results showed that BHK-
Fig. 2. Inhibitory effect of bLF on JEV attachment. The entry of JEV into cells was classiﬁed into two steps, attachment and after attachment, by temperature of incubation, at 4 °C or
37 °C. The effect of bLF on JEV binding to BHK-21 cells was evaluated by ﬂow cytometry at an MOI of 500 (A), and membrane-bound virus by absorption assay at an MOI of 5 (B).
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infection in a dose-dependent manner (Fig. 1C).
Taken together, these results demonstrated clearly that bLF strongly
inhibited the infection of cells by HS-adapted CJN-S1, while only partial
inhibitionwas observed for the non HS-adapted CJN-L1 strain; and the
inhibitory effects were mainly due to the direct binding of bLF to the
cells, not to the virus. In addition, the inhibitory effect showed in Fig.1C
was much less pronounced as compared to Fig. 1A indicating that the
bLF might account for multiple steps during JEV infection.Fig. 3. After JEV binding to BHK-21 cells at 4 °C for 1 h at MOI=5, the bLF was added and
the inhibitory effect was evaluated by an infectious center assay.Effects of bLF on JEV entry
To determinewhether the bLF prevented the binding of JEV to cells
or interfered with a step after virus attached to cells, bLF was added to
the cells either before or after virus binding. First, JEV CJN-S1 and CJN-
L1 were allowed to bind to cells at 4 °C in the presence of various
concentrations of bLF. Unbound virus was removed by washing, and
cell-bound viruses was detected by ﬂow cytometry and quantiﬁed by
plaque assay (Figs. 2A and B). The results showed that binding of the
JEV to BHK-21 cells was inhibited by bLF. Cell binding of HS-adapted
CJN-S1 strain was strongly inhibited by bLF in a dose dependent
manner. By contrast, cell binding of non HS-adapted CJN-L1 virus was
slightly inhibited by bLF and the inhibitory effect was saturated at a
concentration higher than 50 μg/ml.
The effect of bLF on penetration of JEV was evaluated by adding bLF
after virus attached to BHK-21 cells. Virus penetrationwas analyzed by
an infectious center assay (Fig. 3). The results of the infectious center
assay showed that bLF strongly prevented CJN-S1 virus penetration
into BHK-21 cells in a dose dependent manner, whereas CJN-L1 virus
was less affected and the inhibition was saturated at concentrationshigher than 25 μg/ml. These results demonstrate that bLF prevented
JEV entry into cells by inhibiting both attachment and penetration.
Correlation of the inhibitory effect of bLF on JEV infection and
HS-expression
HS is critically involved in JEV infection, primarily at an early stage
of the virus life cycle, including viral attachment and penetration (Liu
et al., 2004; Su et al., 2001). The HS-expressed CHO-K1 and HS-
deﬁcient CHO-pgsA745 cells were used to determine whether the HS
expression played an important role in the inhibitory effect of bLF. JEV
CJN-S1 andCJN-L1were allowed to bind toCHO-K1or-pgsA745 cells at
Fig. 4. Inhibitory effect of bLF on JEV entry into HS-expressed CHO-K1 and HS-deﬁcient CHO-pgsA745 cells. CJN-S1 or CJN-L1 virus binding to bLF-treated CHO-K1 (A) or -pgsA745 (B)
cells was evaluated by ﬂow cytometry at an MOI of 500. For the post-attachment step, bLF was added to JEV-bound cells, and then evaluated by an infectious center assay (C).
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ﬂowcytometry (Figs. 4A and B). The binding of CJN-S1 virus to CHO-K1
cells was more efﬁcient than CJN-L1 (Fig. 4A), and also the binding of
the viruses to CHO-K1 cells was higher than to CHO-pgsA745 cells
(Figs. 4A and B). The binding of CJN-S1 and CJN-L1 viruses were
signiﬁcantly reduced in the presence of 200 μg/ml bLF, but not
completely, in either CHO-K1 or -pgsA745 cells. These resultswere also
conﬁrmed byabsorption assay (data not shown). In CHO-pgsA745 cells
the bLF blocked either 48.6% or 34.9% binding for CJN-S1 or CJN-L1
viruses, respectively.
Subsequently, the infectious center assay was performed to
determine the role of HS in the inhibitory action of bLF after JEV
binding to cells. JEV CJN-S1 and CJN-L1 were allowed to bind to CHO-
K1 or -pgsA745 cells at 4 °C for 1 h, then 200 μg/ml bLF was added and
incubated at 37 °C for additional 1 h, and evaluated by an infectious
center assay (Fig. 4C). This assay showed that bLF prevented the
infection of CHO-K1 or -pgsA745 cells by both CJN-S1 and CJN-L1
viruses. However, bLF was more effective in blocking the CJN-S1 virus
infection in CHO-K1 (11.0±5.4%) than in CHO-pgsA745 (67.7±18.5%)cells, but nearly equal in blocking the CJN-L1 virus infection in both
cells (CHO-K1: 70.1±22.6%; CHO-pgsA745: 87.8±10.7%).
The ability of bLF to block the entry of CJN-S1 virus into CHO-K1
cells more effectively than into CHO-pgsA745 cells suggested that the
HS might play a pivotal role in which the entry of HS-adapted JEV.
However, the previous reports indicated JEV is capable of infecting and
replicating in HS-deﬁcient cells (Chiou et al., 2005; Liu et al., 2004) and
the residue-blocking effect of bLF apparently persisted in CHO-
pgsA745 cells to inhibit CJN-S1 virus entry in present study, suggesting
that a non-HS pathway in both cell types may also contribute to the
initiation of JEV infection.
bLF antagonizes the binding of JEV to heparan sulfate
We next used sepharose-conjugated HS to determine whether bLF
antagonized the binding between JEV particles and HS. The slightly
excess sepharose-conjugatedHSwas incubatedwith bLF; the unbound
bLF and bLF-treated sepharose-conjugated HS were collected sepa-
rately and analyzed. The bLF-treated, sepharose-conjugated HS
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bound-viruses were released by NaCl and quantiﬁed by plaque assay
(Fig. 5A). Preincubation of bLF strongly reduced the binding of CJN-S1
virus to the sepharose-conjugated HS, but not the binding of CJN-L1
virus. The unbound bLF collected from liquid fraction was assayed for
anti-JEV activity (Fig. 5B). Compared to fresh bLF, the unbound bLF
fraction had completely lost its anti-JEV activity, indicating thatmost of
the bLF was bound to the sepharose-conjugated HS. These results
suggested that bLF bound to HS-conjugated sepharose beads, and
prevented the binding of HS-adapted JEV (CJN-S1), but not non HS-
adapted virus (CJN-L1).
Because bLF interacts with HS directly, we investigated whether
heparin could compete with the action of bLF against JEV infection.
Heparin and bLF alone or in combination were mixed with 200 PFU
JEV, and the infectivity was determined by the plaque assay in BHK-21
cells. Pre-incubation of cells with bLF or virus with heparin reduced
the infectivity of CJN-S1 and CJN-L1 signiﬁcantly (Figs. 6A and B).
When a constant concentration of bLF (200 μg/ml) and variable
concentrations of heparin (0.025 to 250 U/ml) were incubated with
virus together, the infectivity of HS-adapted CJN-S1 strain was
signiﬁcantly increased in the presence of 0.025 to 2.5 U/ml heparin.
However, the infectivity decreased when higher concentrations of
heparin (N2.5 to 250 U/ml) were used. These results suggested that
heparin interacts with bLF and antagonizes the inhibitory effect of
both compounds on CJN-S1 virus (Fig. 6A). Non-HS adapted CJN-L1
strain was less dependent on HS for its infection, thus, the addition of
heparin did not affect the inhibitory action of bLF against this virus
(Fig. 6B). In agreement with earlier results, HS played a role in the
inhibitory effect of bLF against HS-adapted JEV. These resultsFig. 5. bLF blocks JEV interaction with heparan sulfate. bLF was allowed to bind to
heparin-sepharose, and the residual bLF and bLF-treated heparin-sepharose were
collected and analyzed separately. bLF-treated heparin-sepharose was incubated with
CJN-S1 or CJN-L1 viruses (5×106 PFU) at 4 °C for adsorption, and the bound virus was
released by NaCl treatment and quantiﬁed by plaque assay (A). The residual bLF was
assayed for anti-JEV infection (B) as described in Fig. 1A.
Fig. 6. Heparin reduced the antiviral activity of bLF. Heparin and bLF alone or in
combination were mixed with 200 PFU JEV CLN-S1 (A) or CJN-L1 (B) strains, and the
infectivity was determined by the plaque assay in BHK-21 cells. (⁎Pb0.05).suggested that an unidentiﬁed non-HS membrane receptor, involved
in the initiation of non-HS adapted JEV infection, may interact with
bLF and reduce the infectivity of CJN-L1 virus.
rLDLR attenuates bLF against JEV
It has been proposed that LDLR binds to bLF and is also involved in
the entry of Flaviviridae viruses (Agnello et al., 1999; Huettinger et al.,
1998). To examine the role of LDLR, 200 PFU of JEV viruses were added
to mixtures of human recombinant LDLR (rLDLR) and bLF, and virus
infectivity was determined by the plaque assay in BHK-21 cells.
Compared to the virus control, the rLDLR alone reduced the infectivity
of CJN-S1 virus to 12.5±4.7% and CJN-L1 virus to 30.0±11.9% (Fig. 7A
and B). Additionally, the receptor-associated protein, binding to LDLR,
also showed the anti-JEV activity, but not human serum albumin.
When a constant concentration of bLF (200 μg/ml) and variable
concentrations of rLDLR were mixed with virus before infection, the
infection of CJN-S1 virus was increased from 12.5% (200 μg/ml bLF
alone) to 54% (bLF+0.8–4 ng/ml rLDLR), whereas the infection of CJN-
L1 virus was increased from 77% (200 μg/ml bLF alone) to 92%
(bLF 100 ng/ml rLDLR). The data showed that rLDLR reduced the
inhibitory effect of bLF against JEV infection, and indicated that rLDLR
may play a role in JEV infection, especially for non HS-adapted strains.
LDLR as a possible receptor for JEV entry
To test whether LDLR plays a role in JEV infection, BHK-21 cells were
pretreated with 5 μg of anti-LDLR, anti-LRP1, anti-VLDLR, anti-SR BI
Fig. 7. Recombinant low density lipoprotein receptor reduced antiviral activity of bLF.
rLDLR and bLF alone or in combinationwere mixed with 200 PFU JEV CLN-S1 (A) or CJN-
L1 (B) strains, and the infectivity was determined by the plaque assay in BHK-21 cells.
(⁎Pb0.05).
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PFU of JEV, and infectivity weremeasured by plaque assay. As shown in
Fig. 8(A), anti-LDLR antibody treatment effectively reduced viral
infectivity by 54% and 23% for CJN-L1 and CJN-S1 viruses, respectively;
in contrast, anti-LRP1, anti-VLDLR, anti-SR BI antibody and normal
chicken serum did not shown signiﬁcant effect. Lovastatin, dissolve in
DMSO, is an inducer of LDLR expression (Molina et al., 2007). BHK-21
cells were cultured with 0 or 10 μM lovastatin for 12 h, and LDLR
expression was measured by ﬂow cytometry to examine the effects of
lovastatin on LDLR expression. As shown in Fig. 8(B), LDLR expression of
lovastain-treated cells was signiﬁcantly higher than the untreated cells.
When treated or untreated cells were infected with CJN-L1 or CJN-S1
virusat anMOI=5 and cultured for 48h (Fig. 8C), the infectivityofCJN-L1
virus in lovastatin-treated cells was signiﬁcantly higher than in
untreated cells (6.31+107 and 1.58+107 PFU/ml, respectively). Similarly,
the infectivity of CJN-S1 virus in lovastatin-treated cells was higher than
in untreated cells (3.16×108 and 7.9×107 PFU/ml, respectively). Finally,
to determine the antiviral activity of bLF on lovastatin-treated BHK-21
cells, we performed a plaque reduction assay with 200 PFU JEV in the
presence of 200 μg/ml of bLF. The results are summarized in Fig. 8D. For
CJN-L1 virus, the inhibitory effect of bLF was 23% and 63% on lovastatin-
untreated and -treated cells, respectively. Similarly for CJN-S1, the
inhibitory effect of bLF on the lovastatin-treated cells was signiﬁcantly
higher than on untreated cells.Discussion
LF suppresses broad-range virus infection, especially mucosally
transmitted viruses, such as herpes simplex virus (Ammendolia et al.,
2007; Andersen et al., 2003, 2004), humanpapillomavirus (Drobni et al.,
2004; Mistry et al., 2007), enterovirus (Lin et al., 2002; Weng et al.,
2005), and human polyomavirus BK (Marchetti et al., 1996). LF also
inhibits the infection of twomosquito-borne alphaviruses, Sindbis virus
(SINV) and Semliki Forest virus (SFV) (Waarts et al., 2005). The
mechanisms of LF in reducing virus infection are the result of LF binding
to the virus particle directly or to the membrane-bound viral receptor
candidate(s) (Andersen et al., 2001; Harmsen et al., 1995; Marchetti et
al.,1996). In the current study,we have shown the anti-JEV action of bLF.
Our results are consistent with alphavirus studies showing that pre-
incubation of virus with 200 μg/ml LF did not inhibit virus infection
(Waarts et al., 2005), and also support reports that LF-sensitive
arboviruses, such as SINV, SFV and JEV, do not interact with LF directly
because of the overall net positive charge nature of both the viral
envelope glycoprotein and LF (Klimstra et al., 1998; Rey et al., 1995).
Reports that pre-incubation of cells with LF suppressed JEV infection is
consistent with the indication that binding of LF to the cell surface
molecule(s), especially molecules with a net negative charge, deter-
mines the antiviral action for arboviruses in general (Waarts et al., 2005).
GAGs, on the cell surface and in the extracellular matrix, bind to a
wide variety of growth factors, chemokines, enzymes, and matrix
components (Bernﬁeld et al., 1992). Previous studies by others have
shown that GAGs are also important in the attachment of a number of
bacteria, protozoa, and viruses (Bergstrom et al., 1997). The highly
sulfated form of GAGs, HS and heparin, on cell surfaces plays a
determining role in the early stage of JEV infection (Chiou et al., 2005;
Lee et al., 2004; Lee and Lobigs, 2002; Liu et al., 2004; Su et al., 2001).
HS is a negatively charged and highly sulfated GAG expressed onmany
types of cells (Bernﬁeld et al., 1992). Proteins typically bind
electrostatically to HS using of stretches of positively charged amino
acids such as Lys and Arg; binding of JEV and bLF to HS is presumably
mediated by the same electrostatic interaction (Chiou et al., 2005; Liu
et al., 2004; Weinberg, 2001). We have demonstrated the binding of
JEV or bLF to HS-sepharose beads and HS-expressed CHO K1 cells, but
not to HS-deﬁcient CHO-pgsA745 cells, and that the binding of bLF to
HS expressed on the cell surface prevented JEV infection. Similar to the
alphavirus study, the HS-adapted JEVs were shown to be more
sensitive to the cells treated with bLF; however, unlike SINV and SFV
(Waarts et al., 2005), the bLF-treated cells also suppressed the
replication of the non HS-adapted, WT JEV strains, although to a
lesser extent. The inconsistent results imply that the interaction
between HS and LF plays a central role in the inhibitory effect of LF
against alphavirus infection, but the bLF-inhibited JEV infection may
involve a non-HS pathway.
Our studies suggested that the inhibitory effect exerted by bLF
treatment may involve multiple steps during JEV entry into cells,
because the binding of virus to cellular membrane and the subsequent
infection of membrane-bound virus were both decreased in the
presence of bLF. This result is consistent with our previous studies
indicating that HS determines the efﬁciency of JEV attachment and
penetration using either BHK-21 or Neuro-2a cells (Liu et al., 2004).
However, LF prevents alphaviruses attachment, and has no inhibitory
effect on attached viruses (Waarts et al., 2005). The inconsistent results
between our JEV study and the alphavirus reports could result from
different experimental protocols. The liposome system, used in SINV
and SFV studies, is advantageous for studying the fusion event
between virus and membrane, but does not mimic all steps of virus
entry, whereas the cell-based system used in present study mimics all
virus entry steps. An earlier study reported that the amino acid at
position 55 of the E2 glycoprotein of SINV is a critical determinant for
binding to HS and effects the internalization of the virus (Dropulic et
al., 1997). Thus, HS may involve JEV, SINV and SFV entry steps before
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or penetration.
SINV is capable of infecting and replicating in HS-deﬁcient cells,
indicating that additional receptors must be involved (Byrnes and
Grifﬁn, 1998). Similarly, JEV has been shown to replicate in HS-
deﬁcient CHO pgsA-745 cells in this and previous reports (Chiou et al.,
2005; Liu et al., 2004). In addition, we found that bLF suppressed the
replication of non HS-adpated JEV in HS-expressed and -deﬁcient
cells, and inhibited replication to a greater extent in HS-adapted
strains in both HS-expressed and -deﬁcient cells. All these observa-
tions suggest that other cell surface expressed, bLF-binding molecule,
in addition to HS, must be involved in JEV entry.
bLF binds to various cellular proteins or molecules, including HS,
LDLR, LRP, and nucleolin (El Yazidi-Belkoura et al., 2001; Huettinger et
al., 1998; Legrand et al., 2004). Among these molecules, LDLR has been
reported to be involved in endocytosis of RNA viruses, including
hepatitis C virus, hepatitis G virus, and bovine viral diarrheal virus
(Agnello et al., 1999). Here, we have shown that interaction between
bLF and rLDLR reduced the inhibitory effect of LF in JEV infection, and
that preincubation of anti-LDLR antibodies with LDLR-expressing cells
reduced the infectivity of both HS-adapted CJN-S1 and non-HS
adapted CJN-L1 viruses. These observations suggested that, in addition
to HS, LDLR may function as a JEV receptor. Compared to HS-adapted
JEV, the nonHS-adapted CJN-L1 strainwasmore sensitive to anti-LDLR
antibody treatment. Most WT JEV strains were the non HS-adapted
phenotype, thus, an LDLR virus receptor may play a key role in theFig. 8. Role of LDLR in JEV infection. BHK-21 cells were pretreated with 5 μg of anti-LDLR ant
reduction assay (A). BHK-21 cells were cultured with 0 or 10 μM lovastatin for 12 h, and the
with JEV at an MOI of 5 for 48 h, and viral infectivity measured by plaque assay (C). Inhibitreplication of JEV in nature (Chiou and Chen, 2007; Klimstra et al.,
1998). The role of LDLR involves in JEV entry need more comprehen-
sive study, especially using non HS-adapted strain other than CJN-L1.
The present study demonstrated the anti-JEV activity of bLF. The
structure, function, and mode of action of bovine lactoferrin or
lactoferricin (pepsin-derived fragment) were similar to human
lactoferrin (Vorland, 1999). LF is produced by neutrophils and mucous
epithelial cells (Vorland, 1999). In the acute phase of JEV infection, the
increase of neutrophils has been observed (Chaturvedi et al., 1979). A
prospective study is required to measure the temporal kinetics of LF
concentration in patient serum during the acute phase of JEV
infection. Higher LF concentration in some patients' sera may account
for a higher probability of inapparent infection in these patients. In
addition, our study also implicates for the ﬁrst time that cell surface-
expressed LDLR may be a possible receptor candidate for JEV. LDLR is
highly expressed in neuronal cells (Dietschy and Turley, 2001; Liou
and Hsu, 1998). Involvement of LDLR in JEV entry might account for
the neurovirulence of the virus.
Materials and methods
Viruses and cell lines
The history of JEV strains (Table 1) used in this study has been
described in our previous report (Chiou and Chen, 2001; Chiou and
Chen, 2007), including ﬁeld-isolated, wild-type strains (T1P1, CC27ibody, subsequently infected with 200 PFU JEV, and infectivity was measured by plaque
LDLR expression was measured by ﬂow cytometry (B), cells were subsequently infected
ory effect of bLF on JEV entry with lovastatin-treated or -nontreated BHK-21 cells (D).
150 Y.-J. Chien et al. / Virology 379 (2008) 143–151and CJN), and laboratory-adapted strains derived from them (T1P1-L4,
T1P1-S1, CJN-L1, CJN-S1, CC27-L1, CC27-L3, CC27-S6 and CC27-S8). The
viral stocks were harvested from the supernatant of infected Aedes
albopictus C6/36 cells, and stored at −70 °C until use.
Cell lines of BHK-21 and C6/36 cells used in this study were
cultured using the protocols described in our previous report (Chiou
and Chen, 2001). Two additional cell lines, CHO-K1 (derived from
Chinese hamster ovary) and its GAG-deﬁcient mutant, pgsA-745, were
grown in Ham's F12K medium containing 2 mM L-glutamine, 1.5 g/L
sodium bicarbonate, and 10% fetal bovine serum (FBS) in a 37 °C
incubator with 5% CO2.
Reagents
bLF (iron unsaturated lactoferrin and purity N90%), human serum
albumin and heparinwere purchased from Sigma (St. Lious, Mo, USA);
heparin-CL-6B (H-CL-6B) sepharose beads, anti-VLDLR antibody, anti-
LRP1 antibody, and human rLDLR were obtained from R&D SYSTEMS
(Minneapolis, MN, USA); anti- SR BI antibody from Novus Biologicals
(Littleton, CO, USA); receptor-associated protein from Calbiochem
(San Diego, CA, USA); chicken anti-LDLR antibody from Chemicon
(Temecula, CA, USA); and anti-JEV mouse hyperimmune serum was a
gift from Dr. GJ. Chang at the Centers for Disease Control (Ft Collins,
CO, USA).
Plaque assay
The procedure for the plaque assay was described previously
(Chiou and Chen, 2001). Brieﬂy, BHK-21 cells were seeded in six-well
plates and incubated at 37 °C for 2 days. The virus samples were
serially diluted in 10-fold dilutions with fresh culture medium
containing 5% FBS. Two hundred μl of diluted viral suspensions were
added to each well, and incubated for 1.5 h at 37 °C with gentle
rocking every 15–20 min. Each well was overlaid with 4 ml of 1.1%
methyl cellulose (Sigma) in culture medium containing 2% FBS. After
incubation at 37 °C for 5 days, cells were ﬁxed with 10%
formaldehyde for 30 min and then stained with 1% crystal violet in
20% ethyl alcohol for 15 min. The virus titer was calculated and
expressed as PFU/ml.
Assays for bLF inhibition of JEV infection
A plaque reduction assaywas performed to determine the antiviral
activity of bLF for JEV. BHK-21 cells were pre-incubated with 0, 0.1, 25,
50, 100, or 200 μg/ml (equals to 0, 0.001, 0.29, 0.57, 1.15, and 2.30 mM)
bLF at 37 °C for 1 h, and the same concentration of bLF wasmaintained
in the overlay media throughout the infection. The bLF-treated BHK-
21cells were infected with 200 PFU of JEV, and the virus titer was
determined by plaque assay.
An absorption assay was used to determine whether the bLF
blocked JEV binding to cells, including BHK-21, CHO-K1(HS-
expressed), and CHO-pgsA745 (HS-deﬁcient). These cells were pre-
incubated with bLF at 4 °C for 1 h, and then incubated with JEV at an
MOI of 5 at 4 °C for 1 hwith gentle rocking every 15–20min. To remove
unbound viruses, cells were washed 3 times with cold PBS. The
adsorbed viruses on the cell membrane were subsequently released
through 3 rounds of freeze (−80 °C)-thaw (37 °C) (Germi et al., 2002).
The resultant virus suspensions were then centrifuged; the super-
natants containing released viruses were titrated by plaque assay.
An infectious center assay was performed to determine whether
the bLF prevented JEV infection after virus binding to cell membranes.
In brief, cells were incubated with virus at 4 °C for 1 h at an MOI of 5.
Subsequently, the infected cells were washed ﬁve times with cold PBS
to remove unbound virus particles and the cells were suspended in
PBS. These cell suspensions were incubated with 0–200 μg/ml bLF at
37 °C for 1 h. After washing, 200 μl of virus-infected, bLF-treated cellswere diluted in 10-fold serial dilutions with fresh culture medium and
co-cultured on BHK-21 cell monolayers for the infectious center assay.
The number of infectious centers per 100 cells was calculated by the
following formula: (number of infectious centers/number of plated
cells in one well)×100.
In vitro heparin-bead binding assay
The binding of JEV to heparin was tested by an in vitro heparin-
bead binding assay as previously described (Byrnes and Grifﬁn, 1998)
with some modiﬁcations. Heparin-CL-6B (H-CL-6B) Sepharose beads
were washed ﬁve times with PBS, and incubated with 0–200 μg/ml of
bLF at 37 °C for 30 min. After washing 3 times with PBS, a 70-μl aliquot
of beads was mixed with viral supernatant in PBS and incubated on a
rotator at 4 °C for 1 h. The bead-bound virus was collected by
centrifugation at 1500 rpm for 10 min. The pelleted beads were then
washed three times with cold PBS. Bead-bound virus was eluted with
250 μl of 400 mM NaCl (prepared in PBS) at 4 °C for 10 min. The input
virus control, unbound virus, and bead-bound virus were titrated
separately by plaque assay. The titers for the bead-bound virus were
estimated using an aliquot diluted 100-fold in order to reduce the NaCl
concentration in the sample.
HS and LDLR blocking assays
Two hundred μg bLF was pre-incubated with 0–250 U/ml heparin
(equals to 0–14.28 μM) or 0–500 ng/ml rLDLR (equals to 0–1.67 nM) in
double-distilled water at 37 °C for 30 min. The mixture was added to
BHK-21 cells which were subsequently infected with 200 PFU JEV at
37 °C for 1 h. The virus titer was determined by plaque assay.
Flow cytometry
Detection of JEV using ﬂow cytometry followed our previous
description (Liu et al., 2004) with some modiﬁcations. In brief, the
cells, including BHK-21, CHO-K1, and CHO-pgsA745, were harvested
from 75-cm2 ﬂasks, using 5 mM EDTA (in PBS). Dissociated cells
(1×106 cells) were incubated with bLF (0–200 μg/ml) at 4 °C for
30 min and washed 3 times with ice-cold PBS. The bLF-treated cells
were incubated with JEV at anMOI of 500 for 1 h at 4 °C, and washed 3
times with ice-cold PBS. The cell-bound JEV was stained by mouse
anti-JEV hyperimmune ascitic ﬂuid at 4 °C for 1 h. Cells were then
washed with PBS three times, and ﬁxed with 0.5% formalin in PBS.
Fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG
antibody was added to the ﬁxed cells, incubated at 4 °C for 1 h, and
washed with PBS three times. Detection and analysis of membrane-
bound JEV was carried out using a FACScan ﬂow cytometer (Becton
Dickinson, Franklin Lakes, NJ).
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